GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 27, 2026.

via HealthDay

WEDNESDAY, May 27, 2026 — A new study suggests GLP-1 medications may slow the spread of certain obesity-related cancers.

"GLP-1 receptor agonists have never been just glucose-lowering drugs," said Dr. Marcin Chwistek, chief of the supportive oncology and palliative care Program at Fox Chase Cancer Center in Philadelphia and an American Society of Clinical Oncology (ASCO) expert in supportive care. "Their anti-inflammatory and immune-modulatory properties have long suggested broader effects."

Researchers analyzed health data from more than 12,000 people who had one of seven types of cancer at stages 1, 2, or 3.

They compared patients who started taking GLP-1 drugs after their diagnosis with similar patients taking another class of diabetes drugs called gliptins.

"Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types," said co-author Dr. Mark David Orland of the Taussig Cancer Institute at the Cleveland Clinic.

The strongest results were seen in lung, breast, colon, and liver cancer, where patients taking GLP-1 medications were found to be 38% to 50% less likely to progress to stage 4 or metastatic cancer.

GLP-1 use was also linked to a 33% lower risk of death overall. The biggest benefit was seen in breast cancer, where the risk of death dropped by 45%.

The anti-inflammatory and immune-related effects of GLP-1s may help explain the findings, according to the authors.

While cautioning that this was an observational study and cannot prove cause and effect, they say the findings are strong enough to justify future clinical trials.

The study is to be presented at ASCO’s annual meeting, taking place in Chicago May 29 to June 2.

Research presented at meetings is considered preliminary until published in a peer-reviewed journal.

Sources

  • HealthDay TV, May 27, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-05-27 22:28

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords